Medindia LOGIN REGISTER
Medindia
Advertisement

PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal

Thursday, October 23, 2008 General News
Advertisement
BOSTON, Oct. 23 PAREXEL InternationalCorporation (Nasdaq: PRXL), a leading global biopharmaceutical servicesprovider, today announced that Alberto Grignolo, Ph.D., Corporate VicePresident, PAREXEL Consulting, has received a Lifetime Achievement Award fromthe Good Clinical Practice Journal (GCPj). Dr. Grignolo was honored at theGCPj Awards ceremony, recognizing excellence in clinical research, which washeld October 22, 2008 at the Banqueting House in London, England.
Advertisement

According to Helena Jensen, Publisher of the Good Clinical PracticeJournal, "GCPj's Lifetime Achievement Award is presented to an exceptionalindividual with a distinguished career in the field of clinical development.We are pleased to honor Dr. Grignolo, who exemplifies dedication to advancingcritical aspects of our industry, and whose achievements are especiallynotable for being consistently forward looking and visionary, from thechampioning of personalized medicine to his current role on the ExecutiveCommittee of the Clinical Trials Transformation Initiative."
Advertisement

"This honor from the GCPj readership and global clinical developmentcommunity is for me not an end but rather a new beginning. This recognition isa challenge to inspire others to pursue our shared mission to prevent and curedisease, while continuing to improve the clinical trial enterprise andworldwide standards and practices to benefit patients. Together, through theimportant work that we do, we can promote innovation, help make personalizedtherapy a reality in our lifetime, meet urgent medical needs, insist onintegrity and ethical behavior, and improve patient access to treatments,"said Dr. Grignolo.

With more than 26 years of experience in regulatory and developmentstrategy, Dr. Alberto Grignolo has helped numerous companies manage businessrisk by promoting effective regulatory strategies and relationships withregulators. Leading a global team of experts at PAREXEL Consulting, Dr.Grignolo oversees the management of regulatory submissions for clients withRegulatory Authorities worldwide. Dr. Grignolo has been an advocate forprogress in personalized drug development, and has helped the industryrecognize emerging opportunities to deliver safe and effective medicines tothe right patients. Prior to joining PAREXEL, Dr. Grignolo served as Presidentof FIDIA Pharmaceutical Corporation, and held management positions inregulatory affairs at Smith Kline & French Laboratories. He has served as anadviser to the Institute of Medicine of the National Academy of Sciences onhuman subject protection in clinical trials. He is currently a member of theExecutive Committee of the Clinical Trials Transformation Initiative (CTTI).Dr. Grignolo has served as a leader of several industry organizations,including as Chairman of RAPS and on the Board of Directors for DIA. Dr.Grignolo holds a Ph.D. in Psychology from the University of North Carolina atChapel Hill and a B.S. degree from Duke University. He completed postdoctoralwork in neuropharmacology at Duke University Medical Center. He is currentlyAdjunct Associate Professor at the Massachusetts College of Pharmacy andHealth Sciences.

Good Clinical Practice Journal (GCPj) (www.gcpj.com) addresses theregulatory, strategic, and clinical issues that directly impact clinicalstudies globally.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceuticalservices organization, providing a broad range of knowledge-based contractresearch, medical communications and consulting services to the worldwidepharmaceutical, biotechnology and medical device industries. Committed toproviding solutions that expedite time-to-market and peak-market penetration,PAREXEL has developed significant expertise across the development andcommercialization continuum, from drug development and regulatory consultingto clinical pharmacology, clinical trials management, medical education andreimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, providesadvanced technology solutions, including medical imaging, to facilitate theclinical development process. Headquartered near Boston, Massachusetts,PAREXEL operates in 69 locations throughout 52 countries around the world, andhas approximately 8,800 employees. For more information about PAREXELInternational visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding futureresults and events. For this purpose, any statements contained herein that arenot statements of historical fact may be deemed forward-looking statements.Without limiting the foregoing, the words "believes," "anticipates," "plans,""expects," "intends," "appears," "estimates," "projects," "targets," andsimilar expressions are also intended to identify forward-looking statements.The forward-looking statements in this release involve a number of risks anduncertainties. The Company's actual future results may differ significantlyfrom the results discussed in the forward-looking statements contained in thisrelease. Important factors that might cause such a difference include, but arenot limited to, risks associated with: actual operating performance; actualexpense savings and other operating improvements resulting from recentrestructurings; the loss, modification, or delay of contracts which would,among other things, adversely impact the Company's recognition of revenueincluded in backlog; the Company's dependence on certain industries andclients; the Company's ability to win new business, manage growth and costs,and attract and retain employees; the Company's ability to complete additionalacquisitions and to integrate newly acquired businesses or enter into newlines of business, including ClinPhone; the impact on the Company's businessof government regulation of the drug, medical device and biotechnologyindustry; consolidation within the pharmaceutical industry and competitionwithin the biopharmaceutical services industry; the potential for significantliability to clients and third parties; the potential adverse impact of healthcare reform; and the effects of exchange rate fluctuations and otherinternational economic, political, and other risks. Such factors and othersare discussed more fully in the section entitled "Risk Factors" of theCompany's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008as filed with the SEC on August 28, 2008, which "Risk Factors" discussion isincorporated by reference in this press release. The forward-lookingstatements included in this press release represent the Company's estimates asof the date of this release. The Company specifically disclaims any obligationto update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company'sestimates or views as of any date subsequent to the date of this pressrelease.

PAREXEL is a registered trademark of PAREXEL International Corporation,and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. Allother names or marks may be registered trademarks or trademarks of PAREXELInternational Corporation, Perceptive Informatics, Inc. or their respectiveowners and are hereby acknowledged.Contacts: Jennifer Baird, Senior Director of Rebecca Passo Public Relations PAREXEL International SHIFT Communications Tel: +781-434-4409 Tel: +617-779-1817 Email: [email protected] Email: [email protected]

SOURCE PAREXEL International Corporation
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close